comparemela.com
Home
Live Updates
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) : comparemela.com
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
—Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 -- CRISPR Therapeutics , a biopharmaceutical...
Related Keywords
Massachusetts ,
United States ,
London ,
City Of ,
United Kingdom ,
Switzerland ,
San Francisco ,
California ,
Boston ,
France ,
Rachel Eides ,
Samarth Kulkarni ,
Susan Kim ,
European Commission ,
European Union ,
Vertex Pharmaceuticals ,
Therapeutics Inc ,
Exchange Commission ,
Vertex Pharmaceuticals Incorporated ,
Globenewswire Inc ,
Nasdaq ,
Chief Executive Officer ,
Sickle Cell Disease ,
Transfusion Dependent Beta Thalassemia ,
Conditional Marketing Authorizations ,
Nobel Prize Winning ,
Private Securities Litigation Reform Act ,
Markets ,
comparemela.com © 2020. All Rights Reserved.